HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Bethke, T. D. Articles by Gleiter, C. H. Search for Related Content PubMed PubMed Citation Articles by Bethke, T. D. Articles by Gleiter, C. H.

Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor

From the Department of Clinical Development Strategy (Dr Bethke), Department of Exploratory Medicine (Dr Hermann, Dr Hauns), Department of Metabolism and Pharmacokinetics (Dr David), Department of Pharmacometrics and Pharmacokinetics (Dr Knoerzer), and Department of Clinical Development Operations and Science (Dr Wurst), ALTANA Pharma AG, Konstanz, Germany, and the Department of Clinical Pharmacology, University Hospital of Tübingen, Tübingen, Germany (Dr Böhmer, Dr Fux, Dr Mörike, Dr Gleiter).

The dose-proportional, intraindividual, single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor under investigation for chronic obstructive pulmonary disease and asthma, was investigated in healthy subjects. In an open, randomized, 2-period, 2-sequence crossover study, 15 subjects received immediate-release tablets of roflumilast 250 or 500 µg as single (day 1) and as repeated, once-daily doses for 8 days (days 5-12). Dose-adjusted point estimates and 90% confidence intervals of test (500 µg)/reference (250 µg) ratios for AUC and C_max of roflumilast and its pharmacologically active N-oxide metabolite after single and repeated dosing were all within the standard equivalence acceptance range (0.80, 1.25) indicating dose proportionality. The pharmacokinetic properties of both roflumilast dosage forms provide clinically relevant evidence of predictable, intraindividual total (AUC) and maximum (C_max) exposure of roflumilast and roflumilast N-oxide. Repeated oral dosing with roflumilast 250 and 500 µg once daily was well tolerated.

Key Words: roflumilast • phosphodiesterase 4 inhibitor • healthy subjects • COPD • asthma

Address for reprints: Dr Christoph H. Gleiter, Abteilung Klinische Pharmakologie, Universitätsklinikum Tübingen, Otfried-Müller-Str. 45, 72076 Tübingen, Germany; e-mail: christoph.gleiter{at}med.uni-tuebingen.de.

This article has been cited by other articles:

				K. A. Neville, S. J. Szefler, S. M. Abdel-Rahman, G. Lahu, K. Zech, R. Herzog, T. D. Bethke, M. C. Gleason, and G. L. Kearns Single-Dose Pharmacokinetics of Roflumilast in Children and Adolescents J. Clin. Pharmacol., August 1, 2008; 48(8): 978 - 985. [Abstract] [Full Text] [PDF]

				R. Hermann, W. Siegmund, T. Giessmann, K. Westphal, A. Weinbrenner, B. Hauns, F. Reutter, G. Lahu, K. Zech, and T. D. Bethke The Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast Lacks Relevant Pharmacokinetic Interactions With Inhaled Budesonide J. Clin. Pharmacol., August 1, 2007; 47(8): 1005 - 1013. [Abstract] [Full Text] [PDF]